Skip to content

Trial Summary

 This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.



ACTRN/NCT /ethics:


Scientific title:

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

Sponsor / Cooperative group:

Yuhan Corporation

Trial & Patient Characteristics

Cancer TypeHER2-Positive Solid Tumor
Trial TypeTreatment
PhasePhase I & Phase II
Age Range18 years and older
Tumour Stream -
Cancer Stage-
Anticipated Start Date2022-08-26
Anticipated End Date2026-10-06

Participating Hospitals

HospitalSouthern Oncology Clinical Research Unit
Clinical Trial CoordinatorMeggan O'Riley
Phone0491 679 039
Principal InvestigatorGanessan Kichenadasse
Recruitment StatusRecruiting